TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer

被引：0
|
作者：
D. Ferraro
D. Goldstein
R. L. O’Connell
J. R. Zalcberg
K. M. Sjoquist
N. C. Tebbutt
P. Grimison
S. McLachlan
L. L. Lipton
P. Vasey
V. J. Gebski
C. Aiken
M. Cronk
S. Ng
C. S. Karapetis
J. Shannon
机构：
[1] University of Sydney,National Health and Medical Research Council Clinical Trials Centre
[2] University of New South Wales,Prince of Wales Clinical School
[3] Monash University,Department of Epidemiology and Preventive Medicine
[4] Austin Health,Haematology and Oncology Clinics of Australasia
[5] Chris O’Brien Lifehouse,Department of Medical Oncology
[6] St Vincents Hospital,Department of Pathology
[7] University of Melbourne,undefined
[8] Western Health,undefined
[9] Wesley Medical Centre,undefined
[10] Nambour General Hospital,undefined
[11] Flinders University,undefined
[12] Nepean Cancer Care Centre,undefined
[13] University of Melbourne,undefined
[14] Sir Charles Gairdner Hospital,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2016年 / 78卷
关键词：
Biliary tract cancer; KRAS; Panitumumab; Chemotherapy; Phase II trial; Cancer antigen 19.9;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：361 / 367
页数：6
相关论文
共 50 条
  • [41] Effects of resveratrol on aortic growth in patients with Marfan syndrome: a single-arm open-label multicentre trial
    van Andel, Mitzi Marlotte
    Bosshardt, Daan
    Schrauben, Eric M.
    Merton, Renske
    van Kimmenade, Roland R. L.
    Scholte, Arthur
    Dickinson, Michael G.
    Robbers-Visser, Danielle
    Zwinderman, Aeilko H.
    Mulder, Barbara
    Nederveen, Aart J.
    van Ooij, Pim
    Groenink, Maarten
    de Waard, Vivian
    HEART, 2025, 111 (01) : 11 - 17
  • [42] A phase II, open-label, single-arm trial of pembrolizumab for refractory atypical and anaplastic meningioma and hemangiopericytoma.
    Yust-Katz, Shlomit
    Amiel, Alexandera
    Siegal, Tali
    Limon, Dror
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial
    Jin, Shuiling
    Zhao, Ruihua
    Zhou, Chuang
    Zhong, Qian
    Shi, Jianxiang
    Su, Chang
    Li, Qinglong
    Su, Xiaoxing
    Chi, Huabin
    Lu, Xu
    Jiang, Guozhong
    Chen, Renyin
    Han, Jinming
    Jiang, Miao
    Qiao, Shishi
    Liu, Jingjing
    Song, Min
    Song, Lijie
    Du, Yabing
    Chang, Zhiwei
    Wang, Meng
    Dong, Meilian
    Zhong, Yali
    Yu, Pu
    Zhang, Xiaojian
    Zong, Hong
    INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (08) : 1648 - 1658
  • [44] A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer
    Hasegawa, Hirotaka
    Shitara, Kohei
    Takiguchi, Shuji
    Takiguchi, Noriaki
    Ito, Seiji
    Kochi, Mitsugu
    Horinouchi, Hidehito
    Kinoshita, Takahiro
    Yoshikawa, Takaki
    Muro, Kei
    Nishikawa, Hiroyoshi
    Suna, Hideaki
    Kodera, Yasuhiro
    GASTRIC CANCER, 2022, 25 (03) : 619 - 628
  • [45] A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer
    Hirotaka Hasegawa
    Kohei Shitara
    Shuji Takiguchi
    Noriaki Takiguchi
    Seiji Ito
    Mitsugu Kochi
    Hidehito Horinouchi
    Takahiro Kinoshita
    Takaki Yoshikawa
    Kei Muro
    Hiroyoshi Nishikawa
    Hideaki Suna
    Yasuhiro Kodera
    Gastric Cancer, 2022, 25 : 619 - 628
  • [46] Gemcitabine and cisplatin or oxaliplatin chemotherapy combined with atezolizumab plus bevacizumab for advanced biliary tract cancers: a single-arm trial
    Wang, Kang
    Yu, Hong-Ming
    Xiang, Yan-Jun
    Cheng, Yu-Qiang
    Ni, Qian-Zhi
    Guo, Wei-Xing
    Shi, Jie
    Feng, Shuang
    Zhai, Jian
    Cheng, Shu-Qun
    FUTURE ONCOLOGY, 2023, 19 (15) : 1029 - 1035
  • [47] Camrelizumab plus concurrent chemoradiotherapy for locally advanced cervical cancer: Preliminary results of a single-arm, open-label, phase II trial
    Xiao, Y.
    Cheng, H.
    Wang, L.
    Yang, L.
    Yu, X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S805 - S805
  • [48] Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial
    Cousin, Sophie
    Cantarel, Coralie
    Guegan, Jean-Philippe
    Gomez-Roca, Carlos
    Metges, Jean-Philippe
    Adenis, Antoine
    Pernot, Simon
    Bellera, Carine
    Kind, Michele
    Auzanneau, Celine
    Le Loarer, Francois
    Soubeyran, Isabelle
    Bessede, Alban
    Italiano, Antoine
    CLINICAL CANCER RESEARCH, 2021, 27 (08) : 2139 - 2147
  • [49] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial
    Wei, W.
    Ban, X.
    Yang, F.
    Huang, Y.
    Li, J.
    Cheng, X.
    Zheng, M.
    Li, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S762 - S762
  • [50] Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial
    De Simone, Michele
    Vaira, Marco
    Argenziano, Monica
    Berchialla, Paola
    Pisacane, Alberto
    Cinquegrana, Armando
    Cavalli, Roberta
    Borsano, Alice
    Robella, Manuela
    BIOMEDICINES, 2020, 8 (05)
12345